Skip to main content
Intended for healthcare professionals
Skip to main content
Restricted access
Research article
First published online July 31, 2017

Mother-to-child HIV-transmission prevention programs in a sub-Saharan African setting: The Gabonese experience

Abstract

In many developing countries, mothers’ awareness remains a challenge despite the scaling up of antenatal care and programs preventing mother-to-child (MTC) HIV transmission. The present study was done in Libreville, Gabon where all antenatal care (delivery included) is free of charge. Here we assessed the timing of antenatal antiretroviral (ARV) prophylaxis initiation, HIV-exposed infants’ age at their first postnatal HIV check visit and investigated the association between mothers’ awareness or knowledge on their ARV therapy and infants’ HIV infection. We interviewed HIV-positive mothers on their first and subsequent laboratory visits to investigate infants’ HIV status and tested infants for HIV RNA and antibody between 2012 and 2014. We established that (1) of 718 HIV-positive mothers, only 6% were fully aware and knew what ARV treatment they were on during pregnancy; (2) half of the women (54%) start their antenatal ARV prophylaxis initiation during the second trimester of pregnancy; (3) 64% of HIV-exposed infants had their first HIV infection screening between birth and three months of age; (4) the overall prevalence of HIV infection in infants born from infected mothers was 8.9%; and (5) infants born from mothers uncertain about taking prophylactic ARV therapy were 13.3 times more likely to be infected by HIV than infants born from mothers certain about taking prophylactic ARV therapy. In conclusion, the study showed that despite free antenatal care, early access and adherence to components of MTC, HIV transmission preventive care remains unsatisfactory.

Get full access to this article

View all access and purchase options for this article.

References

1. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. Lancet Infect Dis 2016; 16: e92–e107.
2. WHO. PMTCT Strategic Vision 2010–2015: preventing mother-to-child transmission of HIV to reach the UNGASS and millennium development goals. WHO Press: Geneva, Switzerland, 2010.
3. Padian NS, McCoy SI, Manian S, et al. Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr 2011; 58: e23–e28.
4. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet 2011; 378: 269–278.
6. Chukwuemeka IK, Fatima MI, Ovavi ZK, et al. The impact of a HIV prevention of mother to child transmission program in a Nigerian early infant diagnosis centre. Niger Med J 2014; 55: 204–208.
7. Newell ML, Brahmbhatt H, Ghys PD. Child mortality and HIV infection in Africa: a review. AIDS 2004; 18: S27–S34.
8. Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis 2015; 61: 1715–1725.
9. Wettstein C, Mugglin C, Egger M, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS 2012; 26: 2361–2373.
10. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86: 304–314.
11. Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. MedGenMed 2005; 7: 4–4.
12. Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. Ther Clin Risk Manag 2005; 1: 189–199.
13. hlarlaithe MO, Grede N, de Pee S, et al. Economic and social factors are some of the most common barriers preventing women from accessing maternal and newborn child health (MNCH) and prevention of mother-to-child transmission (PMTCT) services: a literature review. AIDS Behav 2014; 18: S516–S530.
14. Geary CW, Bukusi EA. Women and ARV-based HIV prevention – challenges and opportunities. J Int AIDS Soc 2014; 17: 19356–19356.